WHAT IS CLAIMED IS:

- A portable DNA sequence comprising a series of nucleotides capable of directing intracellular production of metalloproteinase inhibitors.
- 2. The portable DNA sequence of claim 1 wherein said sequence is capable of directing intracellular production of collagenase inhibitors.
- 3. The portable DNA sequence of claim 1 wherein said nucleotide sequence is:

10	20	30		50	60
GTTGTTGCTG	TGGCTGATAG	CCCCAGCAGG		GTGTCCCACC	CCACCCACAG
70	80	90	100	110 TCGTGGGGAC	120
130	140	150	160	170 CCAAGATGTA	180
190	200	210	220	230	240
CAAGCCTTAG	GGGATGCCGC	TGACATCCGG	TTCGTCTACA	CCCCCGCCAT	GGAGAGTGTC
250	260	270	280	290	300
TGCGGATACT	TCCACAGGTC	CCACAACCGC	AGCGAGGAGT	TTCTCATTGC	TGGAAAACTG
310	320	330	340	350	360
CAGGATGGAC	TCTTGCACAT	CACTACCTGC	AGTTTCGTGG	CTCCCTGGAA	CAGCCTGAGC
370	380	390		410	420
TTAGCTCAGC	GCCGGGGCTT	CACCAAGACC		GCTGTGAGGA	ATGCACAGTG
430	440	450	460	470	
TTTCCCTGTT	TATCCATCCC	CTGCAAACTG	CAGAGTGGCA	CTCATTGCTT	
490	500	510		530	540
CAGCTCCTCC	AAGGCTCTGA	AAAGGGCTTC		ACCTTGCCTG	CCTGCCTCGG
550	560	570		590	600
GAGCCAGGGC	TGTGCACCTG	GCAGTCCCTG		TAGCCTGAAT	CCTGCCCGGA
610 GTGGAAGCTG	620 AAGCCTGCAC	630 AGTGTCCACC			660 CTTCCGGACA
670 ATGAAATAAA	680 GAGTTACCAC				

- 4. The portable DNA sequence of claim 2 wherein said sequence is capable of directing intracellular production of a collagenase inhibitor biologically equivalent to that isolable from human skin fibroblasts.
- 5. A recombinant-DNA cloning vector comprising a nuclectide sequence capable of directing intracellular production of metalloproteinase inhibitors.
- 6. The vector of claim 5 wherein said vector comprises a nucleotide sequence containing at least the following nucleotides:

10	20	30		50	60
GTTGTTGCTG	TGGCTGATAG	CCCCAGCAGG		GTGTCCCACC	CCACCCACAG
70	80	90	100	110	120
ACGGCCTTCT	GCAATTCCGA	CCTCGTCATC	AGGGCCAAGT	TCGTGGGGAC	ACCAGAAGTC
130	140	150	160	170	180
AACCAGACCA	CCTTATACCA	GCGTTATGAG	ATCAAGATGA	CCAAGATGTA	TAAAGGGTTC
190	200	210	220	230	240
CAAGCCTTAG	GGGATGCCGC	TGACATCCGG	TTCGTCTACA	CCCCCGCCAT	GGAGAGTGTC
250	260	270	280	290	300
TGCGGATACT	TCCACAGGTC	CCACAACCGC	AGCGAGGAGT	TTCTCATTGC	TGGAAAACTG
310	320	330	340	350	360
CAGGATGGAC	TCTTGCACAT	CACTACCTGC	AGTTTCGTGG	CTCCCTGGAA	CAGCCTGAGC
370	380	390	400	410	420
TTAGCTCAGC	GCCGGGGCTT	CACCAAGACC	TACACTGTTG	GCTGTGAGGA	ATGCACAGTG
430 TTTCCCTGTT	440 TATCCATCCC	450 CTGCAAACTG		470 CTCATTGCTT	
490	500	510	520	530	540
CAGCTCCTCC	AAGGCTCTGA	AAAGGGCTTC	CAGTCCCGTC	ACCTTGCCTG	CCTGCCTCGG
550	560	570	580	590	
GAGCCAGGGC	TGTGCACCTG	GCAGTCCCTG	CGGTCCCAGA	TAGCCTGAAT	
610 GTGGAAGCTG	620 AAGCCTGCAC	630 AGTGTCCACC		650 TCCCATCTTT	
670 ATGAAATAAA	680 GAGTTACCAC	690 CCAGCAAAAA	700 AAAAAAGGAA	TTC	

- 7. The vector pUC9-F5/237P10.
- 8. A recombinant-DNA method for microbial production of a metalloproteinase inhibitor comprising:
 - (a) preparation of a portable DNA sequence capable of directing a host microorganism to produce a protein having metalloproteinase inhibitor activity;
 - (b) cloning the portable DNA sequence into a vector capable of being transferred into and replicating in a host microorganism, such vector containing operational elements for the portable DNA sequence;
 - (c) transferring the vector containing the portable DNA sequence and operational elements into a host microorganism capable of expressing the metalloproteinase inhibitor protein;
 - (d) culturing the host microorganism under conditions appropriate for amplification of the vector and expression of the inhibitor; and
 - (e) in either order:
 - (i) harvesting the inhibitor; and
 - (ii) causing the inhibitor to assume an active, tertiary structure whereby it possesses metalloproteinase inhibitor activity.
- 9. The method of claim 8 wherein said metalloproteinase inhibitor is collagenase inhibitor.

10. The method of claim 8 wherein said portable DNA sequence is:

10	20	30	40	50	60
GTTGTTGCTG	TGGCTGATAG	CCCCAGCAGG	GCCTGCACCT	GTGTCCCACC	CCACCCACAG
70	80	90	100	110	120
ACGGCCTTCT	GCAATTCCGA	CCTCGTCATC	AGGGCCAAGT	TCGTGGGGAC	ACCAGAAGTC
130	140	150	160	170	180
AACCAGACCA	CCTTATACCA	GCGTTATGAG	ATCAAGATGA	CCAAGATGTA	TAAAGGGTTC
190	200	210	220	230	240
CAAGCCTTAG	GGGATGCCGC	TGACATCCGG	TTCGTCTACA	CCCCCGCCAT	GGAGAGTGTC
250	260	270	280	290	300
TGCGGATACT	TCCACAGGTC	CCACAACCGC	AGCGAGGAGT	TTCTCATTGC	TGGAAAACTG
310	320	330	340	350	360
CAGGATGGAC	TCTTGCACAT	CACTACCTGC	AGTTTCGTGG	CTCCCTGGAA	CAGCCTGAGC
370	380	390	400	410	420
TTAGCTCAGC	GCCGGGGCTT	CACCAAGACC	TACACTGTTG	GCTGTGAGGA	ATGCACAGTG
430	440	450	460	470	480
TTTCCCTGTT	TATCCATCCC	CTGCAAACTG	CAGAGTGGCA	CTCATTGCTT	GTGGACGGAC
490	500	510	520	530	540
CAGCTCCTCC	AAGGCTCTGA	AAAGGGCTTC	CAGTCCCGTC	ACCTTGCCTG	CCTGCCTCGG
550	560	570	580	590	600
GAGCCAGGGC	TGTGCACCTG	GCAGTCCCTG	CGGTCCCAGA	TAGCCTGAAT	CCTGCCCGGA
610	620	630	640	650	660
GTGGAAGCTG	AAGCCTGCAC	AGTGTCCACC	CTGTTCCCAC	TCCCATCTTT	CTTCCGGACA
670 ATGAAATAAA	680 GAGTTACCAC	690 CCAGCAAAAA	700 AAAAAAGGAA	TTC	

- 11. The method of claim 8 wherein said vector containing said portable DNA sequence is pUC9-F5/237P10.
 - 12. The method of claim 8 wherein said host microorganism is a bacterium.
- 13. The method of claim 12 wherein said bacterium is a member of the genus *Bacillus*.
 - 14. The method of claim 13 wherein said bacterium is Bacillus subtilis.

- 15. The method of claim 12 wherein said bacterium is Escherichia coli.
- 16. The method of claim 12 wherein said bacterium is a member of the genus Pseudomonas.
- 17. The method of claim 16 wherein said bacterium is *Pseudomonas* aeruginosa.
 - 18. The method of claim 8 wherein said host microorganism is a yeast.
 - 19. The method of claim 8 wherein said yeast is Saccharomyces cerevisiae.
- 20. The method of claim 8 wherein said inhibitor is harvested prior to being caused to assume said active, tertiary structure.
- 21. The method of claim 8 wherein said inhibitor is caused to assume said active, tertiary structure prior to being harvested.
- 22. A metalloproteinase inhibitor which is biologically equivalent to the collagenase inhibitor isolable from human skin fibroblasts produced by the method of claim 8.
- 23. The microorganism C600/pUC9-F5/237P10 having ATCC Accession No. 53003.
- 24. The portable DNA sequence of claim 1 wherein said nucleotide sequence is:

60	50	40	30	20	10
GGCCCCTTT	AACCCACCAT	GACACCAGAG	CGCCCAGAGA	GCAGATCCAG	GGCCATCGCC
120	110 GCCCCAGCAG	100	90	80	70
180	170	160	150	140	130
CAGGGCCAAG	ACCTCGTCAT	TGCAATTCCG	GACGGCCTTC	CCCACCCACA	TGTGTCCCAC
240	230	220	210	200	190
GATCAAGATG	AGCGTTATGA	ACCTTATACC	CAACCAGACC	CACCAGAAGT	TTCGTGGGA

250 ACCAAGATGT	260 ATAAAGGGTT	270 CCAAGCCTTA		290 CTGACATCCG	
310	320	330	340	350	360
ACCCCCGCCA	TGGAGAGTGT	CTGCGGATAC	TTCCACAGGT	CCCACAACCG	CAGCGAGGAG
370	380	390	400	410	420
TTTCTCATTG	CTGGAAAACT	GCAGGATGGA	CTCTTGCACA	TCACTACCTG	CAGTTTCGTG
430	440	450	460	470	480
GCTCCCTGGA	ACAGCCTGAG	CTTAGCTCAG	CGCCGGGGCT	TCACCAAGAC	CTACACTGTT
490	500	510	520	530	540
GGCTGTGAGG	AATGCACAGT	GTTTCCCTGT	TTATCCATCC	CCTGCAAACT	GCAGAGTGGC
550	560	570		590	600
ACTCATTGCT	TGTGGACGGA	CCAGCTCCTC		AAAAGGGCTT	CCAGTCCCGT
610	620	630	640	650	660
CACCTTGCCT	GCCTGCCTCG	GGAGCCAGGG	CTGTGCACCT	GGCAGTCCCT	GCGGTCCCAG
670	680	690	700	710	720
ATAGCCTGAA	TCCTGCCCGG	AGTGGAAGCT	GAAGCCTGCA	CAGTGTCCAC	CCTGTTCCCA
730 CTCCCATCTT	740 TCTTCCGGAC	750 AATGAAATAA		770 CCCAGCAAAA	